Major depressive disorder.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
24 08 2023
24 08 2023
Historique:
accepted:
11
07
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
epublish
Résumé
Major depressive disorder (MDD) is characterized by persistent depressed mood, loss of interest or pleasure in previously enjoyable activities, recurrent thoughts of death, and physical and cognitive symptoms. People with MDD can have reduced quality of life owing to the disorder itself as well as related medical comorbidities, social factors, and impaired functional outcomes. MDD is a complex disorder that cannot be fully explained by any one single established biological or environmental pathway. Instead, MDD seems to be caused by a combination of genetic, environmental, psychological and biological factors. Treatment for MDD commonly involves pharmacological therapy with antidepressant medications, psychotherapy or a combination of both. In people with severe and/or treatment-resistant MDD, other biological therapies, such as electroconvulsive therapy, may also be offered.
Identifiants
pubmed: 37620370
doi: 10.1038/s41572-023-00454-1
pii: 10.1038/s41572-023-00454-1
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Informations de copyright
© 2023. Springer Nature Limited.
Références
Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019. Global Burden of Disease Collaborative Network https://vizhub.healthdata.org/gbd-results/ (2021).
Reavley, N. J. & Jorm, A. F. Recognition of mental disorders and beliefs about treatment and outcome: findings from an Australian national survey of mental health literacy and stigma. Aust. NZ J. Psychiatry 45, 947–956 (2011).
doi: 10.3109/00048674.2011.621060
Wickersham, A. et al. Systematic review and meta-analysis: the association between child and adolescent depression and later educational attainment. J. Am. Acad. Child Adolesc. Psychiatry 60, 105–118 (2021).
pubmed: 33130250
pmcid: 7779367
doi: 10.1016/j.jaac.2020.10.008
Campbell, D. et al. Effects of depression on employment and social outcomes: a Mendelian randomisation study. J. Epidemiol. Commun. Health 76, 563–571 (2022).
doi: 10.1136/jech-2021-218074
Cheung, K. & Theule, J. Paternal depressive symptoms and parenting behaviors: an updated meta-analysis. J. Child Fam. Stud. 28, 613–626 (2019).
doi: 10.1007/s10826-018-01316-1
Metsä-Simola, N., Martikainen, P. & Monden, C. W. Psychiatric morbidity and subsequent divorce: a couple-level register-based study in Finland. Soc. Psychiatry Psychiatr. Epidemiol. 53, 823–831 (2018).
pubmed: 29721590
doi: 10.1007/s00127-018-1521-2
Rasic, D., Hajek, T., Alda, M. & Uher, R. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. Schizophrenia Bull. 40, 28–38 (2014).
doi: 10.1093/schbul/sbt114
Havinga, P. J. et al. Doomed for disorder? High incidence of mood and anxiety disorders in offspring of depressed and anxious patients: a prospective cohort study. J. Clin. Psychiatry 78, 13086 (2017).
doi: 10.4088/JCP.15m09936
World Health Organization. World Mental Health Report: Transforming Mental Health for All: Executive Summary (WHO, 2022).
Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16, 22–34 (2016).
pubmed: 26711676
pmcid: 5542678
doi: 10.1038/nri.2015.5
Belmaker, R. H. & Agam, G. Major depressive disorder. N. Engl. J. Med. 358, 55–68 (2008).
pubmed: 18172175
doi: 10.1056/NEJMra073096
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (American Psychiatric Association, 2022).
World Health Organization. International Statistical Classification of Diseases and Related Health Problems: Alphabetical Index Vol. 3 (WHO, 2004).
Bauer, M., Severus, E., Möller, H. J. & Young, A. H. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int. J. Psychiatry Clin. Pract. https://doi.org/10.1080/13651501.2017.1306082 (2017).
doi: 10.1080/13651501.2017.1306082
pubmed: 28367707
Marx, W. et al. Clinical guidelines for the use of lifestyle-based mental health care in major depressive disorder: World Federation of Societies for Biological Psychiatry (WFSBP) and Australasian Society of Lifestyle Medicine (ASLM) taskforce. World J. Biol. Psychiatry 24, 333–386 (2022).
pubmed: 36202135
doi: 10.1080/15622975.2022.2112074
Marwaha, S. et al. Novel and emerging treatments for major depression. Lancet 401, 141–153 (2023).
pubmed: 36535295
doi: 10.1016/S0140-6736(22)02080-3
Kahn, R. S. et al. Schizophrenia. Nat. Rev. Dis. Primers 1, 15067 (2015).
pubmed: 27189524
doi: 10.1038/nrdp.2015.67
Vieta, E. et al. Bipolar disorders. Nat. Rev. Dis. Primers 4, 18008 (2018).
pubmed: 29516993
doi: 10.1038/nrdp.2018.8
Gold, S. M. et al. Comorbid depression in medical diseases. Nat. Rev. Dis. Primers 6, 69 (2020). A detailed disease Primer on the relationship between comorbid depression and non-communicable diseases.
pubmed: 32820163
doi: 10.1038/s41572-020-0200-2
Scott, K. M., de Jonge, P., Stein, D. J. & Kessler, R. C. Mental Disorders Around the World: Facts and Figures from the WHO World Mental Health Surveys (Cambridge Univ. Press, 2018).
Moffitt, T. E. et al. How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol. Med. 40, 899–909 (2010).
pubmed: 19719899
doi: 10.1017/S0033291709991036
Ferrari, A. et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol. Med. 43, 471–481 (2013).
pubmed: 22831756
doi: 10.1017/S0033291712001511
World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates (WHO, 2017).
Kuehner, C. Why is depression more common among women than among men? Lancet Psychiatry 4, 146–158 (2017).
pubmed: 27856392
doi: 10.1016/S2215-0366(16)30263-2
Herrman, H. et al. Time for united action on depression: a Lancet–World Psychiatric Association Commission. Lancet 399, 957–1022 (2022). Developed by a Lancet–World Psychiatric Association Commission taskforce, this publication provides a highly detailed overview of a wide range of considerations related to depression.
pubmed: 35180424
doi: 10.1016/S0140-6736(21)02141-3
Solmi, M. et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol. Psychiatry 27, 281–295 (2022).
pubmed: 34079068
doi: 10.1038/s41380-021-01161-7
Ten Have, M. et al. Duration of major and minor depressive episodes and associated risk indicators in a psychiatric epidemiological cohort study of the general population. Acta Psychiatr. Scand. 136, 300–312 (2017).
pubmed: 28512767
doi: 10.1111/acps.12753
Adorjan, K. & Falkai, P. Premature mortality, causes of death, and mental disorders. Lancet 394, 1784–1786 (2019).
pubmed: 31668724
doi: 10.1016/S0140-6736(19)32521-8
GBD Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9, 137–150 (2022).
doi: 10.1016/S2215-0366(21)00395-3
Ferrari, A. J. et al. The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010. PLoS ONE 9, e91936 (2014).
pubmed: 24694747
pmcid: 3973668
doi: 10.1371/journal.pone.0091936
Chesney, E., Goodwin, G. M. & Fazel, S. Risks of all‐cause and suicide mortality in mental disorders: a meta‐review. World Psychiatry 13, 153–160 (2014).
pubmed: 24890068
pmcid: 4102288
doi: 10.1002/wps.20128
Cai, H. et al. Prevalence of suicidality in major depressive disorder: a systematic review and meta-analysis of comparative studies. Front. Psychiatry 12, 190130 (2021).
doi: 10.3389/fpsyt.2021.690130
Gournellis, R. et al. Psychotic (delusional) depression and suicidal attempts: a systematic review and meta‐analysis. Acta Psychiatr. Scand. 137, 18–29 (2018).
pubmed: 29178463
doi: 10.1111/acps.12826
Hawton, K. I., Comabella, C. C., Haw, C. & Saunders, K. Risk factors for suicide in individuals with depression: a systematic review. J. Affect. Disord. 147, 17–28 (2013).
pubmed: 23411024
doi: 10.1016/j.jad.2013.01.004
Malhi, G. S. & Mann, J. J. Depression. Lancet 392, 2299–2312 (2018).
pubmed: 30396512
doi: 10.1016/S0140-6736(18)31948-2
Cuijpers, P., Smit, F. & Furukawa, T. A. Most at‐risk individuals will not develop a mental disorder: the limited predictive strength of risk factors. World Psychiatry 20, 224 (2021).
pubmed: 34002526
pmcid: 8129833
doi: 10.1002/wps.20852
Kendler, K. S. From many to one to many — the search for causes of psychiatric illness. JAMA Psychiatry 76, 1085–1091 (2019).
pubmed: 31215968
doi: 10.1001/jamapsychiatry.2019.1200
Kendler, K. S., Ohlsson, H., Sundquist, K. & Sundquist, J. Sources of parent-offspring resemblance for major depression in a national Swedish extended adoption study. JAMA Psychiatry 75, 194–200 (2018).
pubmed: 29238796
doi: 10.1001/jamapsychiatry.2017.3828
Sullivan, P. F., Neale, M. C. & Kendler, K. S. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 157, 1552–1562 (2000).
pubmed: 11007705
doi: 10.1176/appi.ajp.157.10.1552
Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat. Neurosci. 22, 343–352 (2019).
pubmed: 30718901
pmcid: 6522363
doi: 10.1038/s41593-018-0326-7
Wray, N. R. et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat. Genet. 50, 668–681 (2018).
pubmed: 29700475
pmcid: 5934326
doi: 10.1038/s41588-018-0090-3
Zhang, X. et al. Genome-wide burden of rare short deletions is enriched in major depressive disorder in four cohorts. Biol. Psychiatry 85, 1065–1073 (2019).
pubmed: 31003785
pmcid: 6750266
doi: 10.1016/j.biopsych.2019.02.022
Okbay, A. et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nat. Genet. 48, 624–633 (2016).
pubmed: 27089181
pmcid: 4884152
doi: 10.1038/ng.3552
Anttila, V. et al. Analysis of shared heritability in common disorders of the brain. Science https://doi.org/10.1126/science.aap8757 (2018).
doi: 10.1126/science.aap8757
pubmed: 29930110
Caspi, A. & Moffitt, T. E. All for one and one for all: mental disorders in one dimension. Am. J. Psychiatry 175, 831–844 (2018).
pubmed: 29621902
pmcid: 6120790
doi: 10.1176/appi.ajp.2018.17121383
Hagenaars, S. P. et al. Genetic comorbidity between major depression and cardio‐metabolic traits, stratified by age at onset of major depression. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 183, 309–330 (2020).
doi: 10.1002/ajmg.b.32807
Kendall, K. et al. The genetic basis of major depression. Psychol. Med. 51, 2217–2230 (2021).
pubmed: 33682643
doi: 10.1017/S0033291721000441
Aberg, K. A. et al. Methylome-wide association findings for major depressive disorder overlap in blood and brain and replicate in independent brain samples. Mol. Psychiatry 25, 1344–1354 (2020).
pubmed: 30242228
doi: 10.1038/s41380-018-0247-6
McGowan, P. O. et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 12, 342–348 (2009).
pubmed: 19234457
pmcid: 2944040
doi: 10.1038/nn.2270
Han, L. K. et al. Epigenetic aging in major depressive disorder. Am. J. Psychiatry 175, 774–782 (2018).
pubmed: 29656664
pmcid: 6094380
doi: 10.1176/appi.ajp.2018.17060595
Uchida, S., Yamagata, H., Seki, T. & Watanabe, Y. Epigenetic mechanisms of major depression: targeting neuronal plasticity. Psychiatry Clin. Neurosci. 72, 212–227 (2018).
pubmed: 29154458
doi: 10.1111/pcn.12621
Sahle, B. W. et al. The association between adverse childhood experiences and common mental disorders and suicidality: an umbrella review of systematic reviews and meta-analyses. Eur. Child Adolesc. Psychiatry 21, 1489–1499 (2021).
Kidd, K. N., Prasad, D., Cunningham, J. E., de Azevedo Cardoso, T. & Frey, B. N. The relationship between parental bonding and mood, anxiety and related disorders in adulthood: a systematic review and meta-analysis. J. Affect. Disord. 307, 221–236 (2022).
pubmed: 35378151
doi: 10.1016/j.jad.2022.03.069
Struijs, S. Y. et al. Psychological risk factors and the course of depression and anxiety disorders: a review of 15 years NESDA research. J. Affect. Disord. 295, 1347–1359 (2021).
pubmed: 34706448
doi: 10.1016/j.jad.2021.08.086
Warrier, V. et al. Gene–environment correlations and causal effects of childhood maltreatment on physical and mental health: a genetically informed approach. Lancet Psychiatry 8, 373–386 (2021).
pubmed: 33740410
pmcid: 8055541
doi: 10.1016/S2215-0366(20)30569-1
Wendt, F. R. et al. Multivariate genome-wide analysis of education, socioeconomic status and brain phenome. Nat. Hum. Behav. 5, 482–496 (2021).
pubmed: 33349686
doi: 10.1038/s41562-020-00980-y
Schmaal, L. et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol. Psychiatry 22, 900–909 (2017).
pubmed: 27137745
doi: 10.1038/mp.2016.60
Han, L. K. et al. Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. Mol. Psychiatry 26, 5124–5139 (2021).
pubmed: 32424236
doi: 10.1038/s41380-020-0754-0
Van Velzen, L. S. et al. White matter disturbances in major depressive disorder: a coordinated analysis across 20 international cohorts in the ENIGMA MDD working group. Mol. Psychiatry 25, 1511–1525 (2020).
pubmed: 31471575
doi: 10.1038/s41380-019-0477-2
Chen, F. et al. Hippocampal volume and cell number in depression, schizophrenia, and suicide subjects. Brain Res. 1727, 146546 (2020).
pubmed: 31715144
doi: 10.1016/j.brainres.2019.146546
Cobb, J. A. et al. Hippocampal volume and total cell numbers in major depressive disorder. J. Psychiatr. Res. 47, 299–306 (2013).
pubmed: 23201228
doi: 10.1016/j.jpsychires.2012.10.020
Phillips, J. L., Batten, L. A., Tremblay, P., Aldosary, F. & Blier, P. A prospective, longitudinal study of the effect of remission on cortical thickness and hippocampal volume in patients with treatment-resistant depression. Int. J. Neuropsychopharmacol. 18, pyv037 (2015).
pubmed: 25829180
pmcid: 4571636
doi: 10.1093/ijnp/pyv037
Phillips, J. L., Batten, L. A., Aldosary, F., Tremblay, P. & Blier, P. Brain-volume increase with sustained remission in patients with treatment-resistant unipolar depression. J. Clin. Psychiatry 73, 2102 (2012).
doi: 10.4088/JCP.11m06865
Fries, G. R., Saldana, V. A., Finnstein, J. & Rein, T. Molecular pathways of major depressive disorder converge on the synapse. Mol. Psychiatry 28, 284–297 (2023).
pubmed: 36203007
doi: 10.1038/s41380-022-01806-1
Fried, E. I. & Kievit, R. A. The volumes of subcortical regions in depressed and healthy individuals are strikingly similar: a reinterpretation of the results by Schmaal et al. Mol. Psychiatry 21, 724–725 (2016).
pubmed: 26666203
doi: 10.1038/mp.2015.199
Winter, N. R. et al. Quantifying deviations of brain structure and function in major depressive disorder across neuroimaging modalities. JAMA Psychiatry 79, 879–888 (2022).
pubmed: 35895072
pmcid: 9330277
doi: 10.1001/jamapsychiatry.2022.1780
Schmaal, L. et al. ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharing. Transl Psychiatry 10, 172 (2020).
pubmed: 32472038
pmcid: 7260219
doi: 10.1038/s41398-020-0842-6
Goldstein-Piekarski, A. N. et al. Mapping neural circuit biotypes to symptoms and behavioral dimensions of depression and anxiety. Biol. Psychiatry 91, 561–571 (2022).
pubmed: 34482948
doi: 10.1016/j.biopsych.2021.06.024
Williams, L. M. Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry 3, 472–480 (2016).
pubmed: 27150382
pmcid: 4922884
doi: 10.1016/S2215-0366(15)00579-9
Tang, S. et al. Abnormal amygdala resting-state functional connectivity in adults and adolescents with major depressive disorder: a comparative meta-analysis. EBioMedicine 36, 436–445 (2018).
pubmed: 30316866
pmcid: 6197798
doi: 10.1016/j.ebiom.2018.09.010
Setiawan, E. et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72, 268–275 (2015).
pubmed: 25629589
pmcid: 4836849
doi: 10.1001/jamapsychiatry.2014.2427
Kaiser, R. H., Andrews-Hanna, J. R., Wager, T. D. & Pizzagalli, D. A. Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry 72, 603–611 (2015).
pubmed: 25785575
pmcid: 4456260
doi: 10.1001/jamapsychiatry.2015.0071
McTeague, L. M. et al. Identification of common neural circuit disruptions in emotional processing across psychiatric disorders. Am. J. Psychiatry 177, 411–421 (2020).
pubmed: 31964160
pmcid: 7280468
doi: 10.1176/appi.ajp.2019.18111271
Yan, C.-G. et al. Reduced default mode network functional connectivity in patients with recurrent major depressive disorder. Proc. Natl Acad. Sci. USA 116, 9078–9083 (2019).
pubmed: 30979801
pmcid: 6500168
doi: 10.1073/pnas.1900390116
Greicius, M. D. et al. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol. Psychiatry 62, 429–437 (2007).
pubmed: 17210143
pmcid: 2001244
doi: 10.1016/j.biopsych.2006.09.020
Molendijk, M. et al. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol. Psychiatry 19, 791–800 (2014).
pubmed: 23958957
doi: 10.1038/mp.2013.105
Mousten, I. V., Sørensen, N. V., Christensen, R. H. B. & Benros, M. E. Cerebrospinal fluid biomarkers in patients with unipolar depression compared with healthy control individuals: a systematic review and meta-analysis.JAMA Psychiatry 79, 571–581 (2022).
pubmed: 35442429
pmcid: 9021989
doi: 10.1001/jamapsychiatry.2022.0645
Toda, T., Parylak, S. L., Linker, S. B. & Gage, F. H. The role of adult hippocampal neurogenesis in brain health and disease. Mol. Psychiatry 24, 67–87 (2019).
pubmed: 29679070
doi: 10.1038/s41380-018-0036-2
Boldrini, M. et al. Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology 38, 1068–1077 (2013).
pubmed: 23303074
pmcid: 3629406
doi: 10.1038/npp.2013.5
Lucassen, P. J., Stumpel, M. W., Wang, Q. & Aronica, E. Decreased numbers of progenitor cells but no response to antidepressant drugs in the hippocampus of elderly depressed patients. Neuropharmacology 58, 940–949 (2010).
pubmed: 20138063
doi: 10.1016/j.neuropharm.2010.01.012
Reif, A. et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol. Psychiatry 11, 514–522 (2006).
pubmed: 16415915
doi: 10.1038/sj.mp.4001791
Shi, Y., Luan, D., Song, R. & Zhang, Z. Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: a systematic review and meta-analysis. Eur. Neuropsychopharmacol. 41, 40–51 (2020).
pubmed: 32980240
doi: 10.1016/j.euroneuro.2020.09.633
Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805–809 (2003).
pubmed: 12907793
doi: 10.1126/science.1083328
Holick, K. A., Lee, D. C., Hen, R. & Dulawa, S. C. Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 33, 406–417 (2008).
pubmed: 17429410
doi: 10.1038/sj.npp.1301399
Huang, G., Bannerman, D. & Flint, J. Chronic fluoxetine treatment alters behavior, but not adult hippocampal neurogenesis, in BALB/cJ mice. Mol. Psychiatry 13, 119–121 (2008).
pubmed: 18202694
doi: 10.1038/sj.mp.4002104
Surget, A. et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol. Psychiatry 64, 293–301 (2008).
pubmed: 18406399
doi: 10.1016/j.biopsych.2008.02.022
Miller, B. R. & Hen, R. The current state of the neurogenic theory of depression and anxiety. Curr. Opin. Neurobiol. 30, 51–58 (2015).
pubmed: 25240202
doi: 10.1016/j.conb.2014.08.012
Luan, S., Zhou, B., Wu, Q., Wan, H. & Li, H. Brain-derived neurotrophic factor blood levels after electroconvulsive therapy in patients with major depressive disorder: a systematic review and meta-analysis. Asian J. Psychiatry 51, 101983 (2020).
doi: 10.1016/j.ajp.2020.101983
Vinkers, C. H., Kuzminskaite, E., Lamers, F., Giltay, E. J. & Penninx, B. W. An integrated approach to understand biological stress system dysregulation across depressive and anxiety disorders. J. Affect. Disord. 283, 139–146 (2021).
pubmed: 33549878
doi: 10.1016/j.jad.2021.01.051
Juruena, M. F. Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav. 38, 148–159 (2014).
pubmed: 24269030
doi: 10.1016/j.yebeh.2013.10.020
Waters, R. P. et al. Evidence for the role of corticotropin-releasing factor in major depressive disorder. Neurosci. Biobehav. Rev. 58, 63–78 (2015).
pubmed: 26271720
pmcid: 4828243
doi: 10.1016/j.neubiorev.2015.07.011
Stetler, C. & Miller, G. E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 73, 114–126 (2011).
pubmed: 21257974
doi: 10.1097/PSY.0b013e31820ad12b
Burke, H. M., Davis, M. C., Otte, C. & Mohr, D. C. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology 30, 846–856 (2005).
pubmed: 15961250
doi: 10.1016/j.psyneuen.2005.02.010
Knorr, U., Vinberg, M., Kessing, L. V. & Wetterslev, J. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 35, 1275–1286 (2010).
pubmed: 20447770
doi: 10.1016/j.psyneuen.2010.04.001
Nandam, L. S., Brazel, M., Zhou, M. & Jhaveri, D. J. Cortisol and major depressive disorder — translating findings from humans to animal models and back. Front. Psychiatry 10, 974 (2020).
pubmed: 32038323
pmcid: 6987444
doi: 10.3389/fpsyt.2019.00974
Zajkowska, Z. et al. Cortisol and development of depression in adolescence and young adulthood–a systematic review and meta-analysis. Psychoneuroendocrinology 136, 105625 (2021).
pubmed: 34920399
doi: 10.1016/j.psyneuen.2021.105625
Kennis, M. et al. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Mol. Psychiatry 25, 321–338 (2020).
pubmed: 31745238
doi: 10.1038/s41380-019-0585-z
Judd, L. L. et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am. J. Psychiatry 171, 1045–1051 (2014).
pubmed: 25272344
doi: 10.1176/appi.ajp.2014.13091264
Ding, Y., Wei, Z., Yan, H. & Guo, W. Efficacy of treatments targeting hypothalamic-pituitary-adrenal systems for major depressive disorder: a meta-analysis. Front. Pharmacol. 12, 732157 (2021).
pubmed: 34566653
pmcid: 8461240
doi: 10.3389/fphar.2021.732157
Dwyer, J. B. et al. Hormonal treatments for major depressive disorder: state of the art. Am. J. Psychiatry 177, 686–705 (2020).
pubmed: 32456504
pmcid: 7841732
doi: 10.1176/appi.ajp.2020.19080848
Osimo, E. F. et al. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav. Immun. 87, 901–909 (2020).
pubmed: 32113908
pmcid: 7327519
doi: 10.1016/j.bbi.2020.02.010
Mac Giollabhui, N., Ng, T. H., Ellman, L. M. & Alloy, L. B. The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression. Mol. Psychiatry 26, 3302–3314 (2021).
doi: 10.1038/s41380-020-00867-4
Lee, C. H. & Giuliani, F. The role of inflammation in depression and fatigue. Front. Immunol. 10, 1696 (2019).
pubmed: 31379879
pmcid: 6658985
doi: 10.3389/fimmu.2019.01696
Patten, S. B., Marrie, R. A. & Carta, M. G. Depression in multiple sclerosis. Int. Rev. Psychiatry 29, 463–472 (2017).
pubmed: 28681616
doi: 10.1080/09540261.2017.1322555
Chiu, W., Su, Y., Su, K. & Chen, P. Recurrence of depressive disorders after interferon-induced depression. Transl Psychiatry 7, e1026 (2017).
pubmed: 28170005
pmcid: 5438022
doi: 10.1038/tp.2016.274
Uzzan, S. & Azab, A. N. Anti-TNF-α compounds as a treatment for depression. Molecules 26, 2368 (2021).
pubmed: 33921721
pmcid: 8073844
doi: 10.3390/molecules26082368
Raison, C. L. et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 31–41 (2013).
pubmed: 22945416
pmcid: 4015348
doi: 10.1001/2013.jamapsychiatry.4
McIntyre, R. S. et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry 76, 783–790 (2019).
pubmed: 31066887
pmcid: 6506894
doi: 10.1001/jamapsychiatry.2019.0779
Köhler‐Forsberg, O. et al. Efficacy of anti‐inflammatory treatment on major depressive disorder or depressive symptoms: meta‐analysis of clinical trials. Acta Psychiatr. Scand. 139, 404–419 (2019).
pubmed: 30834514
doi: 10.1111/acps.13016
Baune, B. T. et al. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: a 6-week double-blind placebo controlled randomized trial. Eur. Neuropsychopharmacol. 53, 34–46 (2021).
pubmed: 34375789
doi: 10.1016/j.euroneuro.2021.07.092
Hellmann-Regen, J. et al. Effect of minocycline on depressive symptoms in patients with treatment-resistant depression: a randomized clinical trial. JAMA Netw. Open 5, e2230367 (2022).
pubmed: 36103181
pmcid: 9475381
doi: 10.1001/jamanetworkopen.2022.30367
Wang, L. et al. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis. Brain Behav. Immun. 79, 24–38 (2019).
pubmed: 30797959
doi: 10.1016/j.bbi.2019.02.021
Gay, F., Romeo, B., Martelli, C., Benyamina, A. & Hamdani, N. Cytokines changes associated with electroconvulsive therapy in patients with treatment-resistant depression: a meta-analysis. Psychiatry Res. 297, 113735 (2021).
pubmed: 33497973
doi: 10.1016/j.psychres.2021.113735
Arteaga-Henríquez, G. et al. Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium. Front. Psychiatry 10, 458 (2019).
pubmed: 31354538
pmcid: 6630191
doi: 10.3389/fpsyt.2019.00458
Enache, D., Pariante, C. M. & Mondelli, V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav. Immun. 81, 24–40 (2019).
pubmed: 31195092
doi: 10.1016/j.bbi.2019.06.015
Morris, G. et al. Leaky brain in neurological and psychiatric disorders: drivers and consequences. Austr. NZ J. Psychiatry 52, 924–948 (2018).
doi: 10.1177/0004867418796955
Miller, A. H., Maletic, V. & Raison, C. L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732–741 (2009).
pubmed: 19150053
pmcid: 2680424
doi: 10.1016/j.biopsych.2008.11.029
Cryan, J. F. et al. The microbiota-gut-brain axis. Physiol. Rev. 99, 1877–2013 (2019). A seminal review of the mechanisms, preclinical evidence and clinical trial data that have investigated the role of the gut–brain axis in psychiatry.
pubmed: 31460832
doi: 10.1152/physrev.00018.2018
Rutsch, A., Kantsjö, J. B. & Ronchi, F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front. Immunol. 11, 604179 (2020).
pubmed: 33362788
pmcid: 7758428
doi: 10.3389/fimmu.2020.604179
Bonaz, B., Bazin, T. & Pellissier, S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front. Neurosci. 12, 49 (2018).
pubmed: 29467611
pmcid: 5808284
doi: 10.3389/fnins.2018.00049
O’Riordan, K. J. et al. Short chain fatty acids: microbial metabolites for gut-brain axis signalling. Mol. Cell. Endocrinol. 546, 111572 (2022).
pubmed: 35066114
doi: 10.1016/j.mce.2022.111572
Resende, W. R. et al. Effects of sodium butyrate in animal models of mania and depression: implications as a new mood stabilizer. Behav. Pharmacol. 24, 569–579 (2013).
pubmed: 23994816
doi: 10.1097/FBP.0b013e32836546fc
Luczynski, P. et al. Growing up in a bubble: using germ-free animals to assess the influence of the gut microbiota on brain and behavior. Int. J. Neuropsychopharmacol. 19, pyw020 (2016).
pubmed: 26912607
pmcid: 5006193
doi: 10.1093/ijnp/pyw020
Clarke, G. et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol. Psychiatry 18, 666–673 (2013).
pubmed: 22688187
doi: 10.1038/mp.2012.77
Kelly, J. R. et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J. Psychiatr. Res. 82, 109–118 (2016).
pubmed: 27491067
doi: 10.1016/j.jpsychires.2016.07.019
Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol. Psychiatry 21, 786–796 (2016).
pubmed: 27067014
doi: 10.1038/mp.2016.44
McGuinness, A. et al. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol. Psychiatry 27, 1920–1935 (2022).
pubmed: 35194166
pmcid: 9126816
doi: 10.1038/s41380-022-01456-3
Van de Wouw, M. et al. Short‐chain fatty acids: microbial metabolites that alleviate stress‐induced brain–gut axis alterations. J. Physiol. 596, 4923–4944 (2018).
pubmed: 30066368
pmcid: 6187046
doi: 10.1113/JP276431
Vujkovic-Cvijin, I. et al. Host variables confound gut microbiota studies of human disease. Nature 587, 448–454 (2020).
pubmed: 33149306
pmcid: 7677204
doi: 10.1038/s41586-020-2881-9
Berding, K. et al. Diet and the microbiota–gut–brain axis: sowing the seeds of good mental health. Adv. Nutr. https://doi.org/10.1093/advances/nmaa181 (2021).
doi: 10.1093/advances/nmaa181
pubmed: 33693453
pmcid: 8321864
Green, J. E. et al. Feasibility, acceptability, and safety of faecal microbiota transplantation in the treatment of major depressive disorder: a pilot randomized controlled trial. Can. J. Psychiatry 68, 315–326 (2023).
pubmed: 36637229
doi: 10.1177/07067437221150508
Liu, R. T., Walsh, R. F. & Sheehan, A. E. Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials. Neurosci. Biobehav. Rev. 102, 13–23 (2019).
pubmed: 31004628
pmcid: 6584030
doi: 10.1016/j.neubiorev.2019.03.023
Stein, D. J. et al. Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. BMC Med. 18, 21 (2020).
pubmed: 31983345
pmcid: 6983973
doi: 10.1186/s12916-020-1495-2
Zimmerman, M., McGlinchey, J. B., Young, D. & Chelminski, I. Diagnosing major depressive disorder I: a psychometric evaluation of the DSM-IV symptom criteria. J. Nerv. Ment. Dis. 194, 158–163 (2006).
pubmed: 16534432
doi: 10.1097/01.nmd.0000202239.20315.16
Lux, V. & Kendler, K. S. Deconstructing major depression: a validation study of the DSM-IV symptomatic criteria. Psychol. Med. 40, 1679–1690 (2010).
pubmed: 20059797
pmcid: 3010198
doi: 10.1017/S0033291709992157
Cuijpers, P. & Smit, F. Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies. Acta Psychiatr. Scand. 109, 325–331 (2004).
pubmed: 15049768
doi: 10.1111/j.1600-0447.2004.00301.x
Tuithof, M. et al. Course of subthreshold depression into a depressive disorder and its risk factors. J. Affect. Disord. 241, 206–215 (2018).
pubmed: 30130686
doi: 10.1016/j.jad.2018.08.010
Karyotaki, E. et al. Internet-based cognitive behavioral therapy for depression: a systematic review and individual patient data network meta-analysis. JAMA Psychiatry 78, 361–371 (2021).
pubmed: 33471111
doi: 10.1001/jamapsychiatry.2020.4364
Cuthbert, B. N. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 13, 28–35 (2014).
pubmed: 24497240
pmcid: 3918011
doi: 10.1002/wps.20087
Kotov, R. et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): a dimensional alternative to traditional nosologies. J. Abnorm. Psychol. 126, 454–477 (2017).
pubmed: 28333488
doi: 10.1037/abn0000258
Krueger, R. F. et al. Progress in achieving quantitative classification of psychopathology. World Psychiatry 17, 282–293 (2018).
pubmed: 30229571
pmcid: 6172695
doi: 10.1002/wps.20566
Weinberger, D. R., Glick, I. D. & Klein, D. F. Whither research domain criteria (RDoC)?: The good, the bad, and the ugly. JAMA Psychiatry 72, 1161–1162 (2015).
pubmed: 26558844
doi: 10.1001/jamapsychiatry.2015.1743
Ross, C. A. & Margolis, R. L. Research domain criteria: strengths, weaknesses, and potential alternatives for future psychiatric research. Mol. Neuropsychiatry 5, 218–236 (2019).
pubmed: 31768375
pmcid: 6873013
Cheung, R. Y. M. in Handbook of Assessment in Mindfulness Research (eds Medvedev, O. N., Krägeloh, C. U., Siegert, R. J. & Singh, N. N.) (Springer, 2023).
Levis, B., Benedetti, A. & Thombs, B. D. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. Br. Med. J. 365, l1476 (2019).
doi: 10.1136/bmj.l1476
El-Den, S., Chen, T. F., Gan, Y.-L., Wong, E. & O’Reilly, C. L. The psychometric properties of depression screening tools in primary healthcare settings: a systematic review. J. Affect. Disord. 225, 503–522 (2018).
pubmed: 28866295
doi: 10.1016/j.jad.2017.08.060
Oyama, H. & Sakashita, T. Differences in specific depressive symptoms among community-dwelling middle-aged Japanese adults before and after a universal screening intervention. Soc. Psychiatry Psychiatr. Epidemiol. 49, 251–258 (2014).
pubmed: 23824236
doi: 10.1007/s00127-013-0735-6
UK National Screening Committee. Screening for Depression in Adults. UK National Screening Committee https://view-health-screening-recommendations.service.gov.uk/review/depression-2020/download-documents/cover_sheet/ (2020).
National Institute for Health and Care Excellence. Depression in Adults: Treatment and Management (Update). National Institute for Health and Care Excellence https://www.nice.org.uk/guidance/ng222 (2022).
Joffres, M. et al. Recommendations on screening for depression in adults. Can. Med. Assoc. J. 185, 775–782 (2013).
doi: 10.1503/cmaj.130403
Keshavarz, H. et al. Screening for Depression. McMaster Evidence Review and Synthesis Centre http://canadiantaskforce.ca/wp-content/uploads/2013/06/2013-depression-systematic-review-en.pdf (2012).
Siu, A. L. et al. Screening for depression in adults: US Preventive Services Task Force recommendation statement. J. Am. Med. Assoc. 315, 380–387 (2016).
doi: 10.1001/jama.2015.18392
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9, 137–150 (2022). Developed by the Global Burden of Disease Study, this publication provides a detailed analysis of the global burden of mental disorders.
pmcid: 8776563
doi: 10.1016/S2215-0366(21)00395-3
Porsdam Mann, S., Bradley, V. J. & Sahakian, B. J. Human rights-based approaches to mental health: a review of programs. Health Hum. Rights 18, 263–276 (2016).
pubmed: 27781015
pmcid: 5070696
O’Neil, A. et al. A shared framework for the common mental disorders and non-communicable disease: key considerations for disease prevention and control. BMC Psychiatry 15, 15 (2015).
pubmed: 25652365
pmcid: 4342822
doi: 10.1186/s12888-015-0394-0
Cuijpers, P. et al. Psychological interventions to prevent the onset of depressive disorders: a meta-analysis of randomized controlled trials. Clin. Psychol. Rev. 83, 101955 (2021).
pubmed: 33333441
doi: 10.1016/j.cpr.2020.101955
Spence, S. H., Sheffield, J. K. & Donovan, C. L. Preventing adolescent depression: an evaluation of the problem solving for life program. J. Consult. Clin. Psychol. 71, 3 (2003).
pubmed: 12602420
doi: 10.1037/0022-006X.71.1.3
Werner-Seidler, A., Perry, Y., Calear, A. L., Newby, J. M. & Christensen, H. School-based depression and anxiety prevention programs for young people: a systematic review and meta-analysis. Clin. Psychol. Rev. 51, 30–47 (2017).
pubmed: 27821267
doi: 10.1016/j.cpr.2016.10.005
Arnarson, E. O. & Craighead, W. E. Prevention of depression among Icelandic adolescents: a 12-month follow-up. Behav. Res. Ther. 49, 170–174 (2011).
pubmed: 21296338
doi: 10.1016/j.brat.2010.12.008
Arnarson, E. Ö. & Craighead, W. E. Prevention of depression among Icelandic adolescents. Behav. Res. Ther. 47, 577–585 (2009).
pubmed: 19411074
doi: 10.1016/j.brat.2009.03.011
Matos, A. P. et al. Prevention of initial depressive disorders among at-risk Portuguese adolescents. Behav. Ther. 50, 743–754 (2019).
pubmed: 31208684
doi: 10.1016/j.beth.2018.11.005
Berk, M. et al. Effect of aspirin vs placebo on the prevention of depression in older people: a randomized clinical trial. JAMA Psychiatry 77, 1012–1020 (2020).
pubmed: 32492080
doi: 10.1001/jamapsychiatry.2020.1214
Okereke, O. I. et al. Effect of long-term supplementation with marine omega-3 fatty acids vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. J. Am. Med. Assoc. 326, 2385–2394 (2021).
doi: 10.1001/jama.2021.21187
Okereke, O. I. et al. Effect of long-term vitamin D3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. J. Am. Med. Assoc. 324, 471–480 (2020).
doi: 10.1001/jama.2020.10224
Firth, J. et al. A meta‐review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry 19, 360–380 (2020).
pubmed: 32931092
pmcid: 7491615
doi: 10.1002/wps.20773
Reynolds, C. F. III et al. Early intervention to preempt major depression among older black and white adults. Psychiatr. Serv. 65, 765–773 (2014).
pubmed: 24632760
pmcid: 4050338
doi: 10.1176/appi.ps.201300216
Bot, M. et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms: the MooDFOOD randomized clinical trial. J. Am. Med. Assoc. 321, 858–868 (2019).
doi: 10.1001/jama.2019.0556
Bauer, M. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J. Biol. Psychiatry https://doi.org/10.3109/15622975.2014.1001786 (2015).
doi: 10.3109/15622975.2014.1001786
pubmed: 25677972
Kennedy, S. H. et al. Canadian Network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can. J. Psychiatry 61, 540–560 (2016).
pubmed: 27486148
pmcid: 4994790
doi: 10.1177/0706743716659417
Malhi, G. S. et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust. NZ J. Psychiatry 55, 7–117 (2021).
doi: 10.1177/0004867420979353
Maj, M. et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry 19, 269–293 (2020).
pubmed: 32931110
pmcid: 7491646
doi: 10.1002/wps.20771
Macneil, C. A., Hasty, M. K., Conus, P. & Berk, M. Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. BMC Med. 10, 111 (2012).
pubmed: 23016556
pmcid: 3523045
doi: 10.1186/1741-7015-10-111
Kok, R. M. & Reynolds, C. F. Management of depression in older adults: a review. J. Am. Med. Assoc. 317, 2114–2122 (2017).
doi: 10.1001/jama.2017.5706
Shalaby, R. A. H. & Agyapong, V. I. Peer support in mental health: literature review. JMIR Ment. Health 7, e15572 (2020).
pubmed: 32357127
pmcid: 7312261
doi: 10.2196/15572
Demyttenaere, K. et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. J. Am. Med. Assoc. 291, 2581–2590 (2004).
doi: 10.1001/jama.291.21.2581
Thornicroft, G. et al. Undertreatment of people with major depressive disorder in 21 countries. Br. J. Psychiatry 210, 119–124 (2017).
pubmed: 27908899
pmcid: 5288082
doi: 10.1192/bjp.bp.116.188078
World Health Organization. Mental Health Atlas 2020. WHO https://www.who.int/publications/i/item/9789240036703 (2021).
World Health Organization. mhGAP Intervention Guide for Mental, Neurological and Substance Use Disorders in Non-specialized Health Settings: Mental Health Gap Action Programme (mhGAP) (WHO, 2016).
Ndetei, D. M., Mutiso, V. & Osborn, T. Moving away from the scarcity fallacy: three strategies to reduce the mental health treatment gap in LMICs. World Psychiatry 22, 163 (2023).
pubmed: 36640407
pmcid: 9840495
doi: 10.1002/wps.21054
Cuijpers, P. et al. Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care: a network meta-analysis. Ann. Fam. Med. 19, 262 LP–262270 (2021).
doi: 10.1370/afm.2676
Furukawa, T. A. et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World Psychiatry 20, 387–396 (2021).
pubmed: 34505365
pmcid: 8429344
doi: 10.1002/wps.20906
Cuijpers, P. et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry 20, 283–293 (2021).
pubmed: 34002502
pmcid: 8129869
doi: 10.1002/wps.20860
Furukawa, T. A. et al. Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data. Lancet Psychiatry 8, 500–511 (2021).
pubmed: 33957075
pmcid: 8838916
doi: 10.1016/S2215-0366(21)00077-8
Andersson, G., Cuijpers, P., Carlbring, P., Riper, H. & Hedman, E. Guided Internet‐based vs. face‐to‐face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta‐analysis. World Psychiatry 13, 288–295 (2014).
pubmed: 25273302
pmcid: 4219070
doi: 10.1002/wps.20151
Cuijpers, P., Noma, H., Karyotaki, E., Cipriani, A. & Furukawa, T. A. Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: a network meta-analysis. JAMA Psychiatry 76, 700–707 (2019).
pubmed: 30994877
pmcid: 6583673
doi: 10.1001/jamapsychiatry.2019.0268
Zohar, J. & Levy, D. M. Neuroscience-based nomenclature of psychotropics: progress report. Eur. Neuropsychopharmacol. 57, 36–38 (2022).
pubmed: 35077943
doi: 10.1016/j.euroneuro.2022.01.002
Zohar, J. et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur. Neuropsychopharmacol. 25, 2318–2325 (2015). Provides an introduction to Neuroscience-based Nomenclature, a system for standardizing nomenclature of psychiatric medications.
pubmed: 26527055
doi: 10.1016/j.euroneuro.2015.08.019
Taylor, M. J., Freemantle, N., Geddes, J. R. & Bhagwagar, Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch. Gen. Psychiatry 63, 1217–1223 (2006).
pubmed: 17088502
pmcid: 2211759
doi: 10.1001/archpsyc.63.11.1217
Leichsenring, F., Steinert, C., Rabung, S. & Ioannidis, J. P. A. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. World Psychiatry 21, 133–145 (2022). An umbrella review of 102 meta-analyses of RCTs that investigated the effect of psychotherapies and pharmacotherapies for multiple mental disorders.
pubmed: 35015359
pmcid: 8751557
doi: 10.1002/wps.20941
Maslej, M. M. et al. Individual differences in response to antidepressants: a meta-analysis of placebo-controlled randomized clinical trials. JAMA Psychiatry 78, 490–497 (2021).
pubmed: 33595620
doi: 10.1001/jamapsychiatry.2020.4564
Cipriani, A. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus 16, 420–429 (2018). This systematic review and meta-analysis compares several antidepressant medications across efficacy, acceptability and tolerability outcomes.
pubmed: 32021580
pmcid: 6996085
doi: 10.1176/appi.focus.16407
Undurraga, J. & Baldessarini, R. J. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37, 851–864 (2012).
pubmed: 22169941
doi: 10.1038/npp.2011.306
Correll, C. U. et al. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry 20, 244–275 (2021). An umbrella review of 14 network meta-analyses and 90 meta-analyses that investigated the role of several intervention modalities on 15 mental disorders in children and adolescents.
pubmed: 34002501
pmcid: 8129843
doi: 10.1002/wps.20881
Zhou, X. et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry 7, 581–601 (2020).
pubmed: 32563306
pmcid: 7303954
doi: 10.1016/S2215-0366(20)30137-1
Yan, Y. et al. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Psychol. Med. 52, 2224–2231 (2022).
pubmed: 35993319
doi: 10.1017/S0033291722001246
Lenze, E. J. et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet 386, 2404–2412 (2015).
pubmed: 26423182
pmcid: 4690746
doi: 10.1016/S0140-6736(15)00308-6
Lenze, E. J. et al. Antidepressant augmentation versus switch in treatment-resistant geriatric depression. N. Engl. J. Med. 388, 1067–1079 (2023).
pubmed: 36867173
doi: 10.1056/NEJMoa2204462
Rost, N., Binder, E. B. & Brückl, T. M. Predicting treatment outcome in depression: an introduction into current concepts and challenges. Eur. Arch. Psychiatry Clin. Neurosci. 273, 113–127 (2023).
pubmed: 35587279
doi: 10.1007/s00406-022-01418-4
Abi‐Dargham, A. et al. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry 22, 236–262 (2023).
pubmed: 37159365
pmcid: 10168176
doi: 10.1002/wps.21078
Bradley, P. et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J. Psychiatr. Res. 96, 100–107 (2018).
pubmed: 28992526
doi: 10.1016/j.jpsychires.2017.09.024
Han, C. et al. A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial. Clin. Psychopharmacol. Neurosci. 16, 469 (2018).
pubmed: 30466219
pmcid: 6245286
doi: 10.9758/cpn.2018.16.4.469
Oslin, D. W. et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME Care randomized clinical trial. J. Am. Med. Assoc. 328, 151–161 (2022).
doi: 10.1001/jama.2022.9805
Iosifescu, D. V. Pharmacogenomic testing for next-step antidepressant selection: still a work in progress. J. Am. Med. Assoc. 328, 146–148 (2022).
doi: 10.1001/jama.2022.10018
Moraczewski, J. & Aedma, K. K. Tricyclic Antidepressants. StatPearls [online] https://www.ncbi.nlm.nih.gov/books/NBK557791/ (updated 21 November 2022).
Kuhn, M., Letunic, I., Jensen, L. J. & Bork, P. The SIDER database of drugs and side effects. Nucleic Acids Res. 44, D1075–D1079 (2016).
pubmed: 26481350
doi: 10.1093/nar/gkv1075
Croatto, G. et al. The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: an umbrella review of the evidence from randomised controlled trials. Mol. Psychiatry https://doi.org/10.1038/s41380-022-01770-w (2022). This umbrella review included 97 meta-analyses to explore the association between pharmacological and non-pharmacological interventions on physical health outcomes.
doi: 10.1038/s41380-022-01770-w
pubmed: 36138129
pmcid: 9493151
Dragioti, E. et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry 76, 1241–1255 (2019). An umbrella review of 45 meta-analyses of observational studies that have investigated the association between antidepressant use and adverse health outcomes.
pubmed: 31577342
pmcid: 6777224
doi: 10.1001/jamapsychiatry.2019.2859
Pratt, L. A., Brody, D. J. & Gu, Q. Antidepressant Use in Persons Aged 12 and Over: United States, 2005–2008 (US Department of Health and Human Services, Centers for Disease Control, 2011).
Lewis, G. et al. Maintenance or discontinuation of antidepressants in primary care. N. Engl. J. Med. 385, 1257–1267 (2021).
pubmed: 34587384
doi: 10.1056/NEJMoa2106356
Warner, C. H., Bobo, W., Warner, C. M., Reid, S. & Rachal, J. Antidepressant discontinuation syndrome. Am. Fam. Physician 74, 449–456 (2006).
pubmed: 16913164
Hyde, J. et al. Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials. Mol. Psychiatry 27, 2709–2719 (2022).
pubmed: 35365806
pmcid: 8973679
doi: 10.1038/s41380-022-01524-8
Espinoza, R. T. & Kellner, C. H. Electroconvulsive therapy. N. Engl. J. Med. 386, 667–672 (2022).
pubmed: 35172057
doi: 10.1056/NEJMra2034954
Husain, M. M. et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J. Clin. Psychiatry 65, 19907 (2004).
doi: 10.4088/JCP.v65n0406
Bahji, A., Hawken, E., Sepehry, A., Cabrera, C. & Vazquez, G. ECT beyond unipolar major depression: systematic review and meta‐analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatr. Scand. 139, 214–226 (2019).
pubmed: 30506992
Meyer, J. P., Swetter, S. K. & Kellner, C. H. Electroconvulsive therapy in geriatric psychiatry: a selective review. Psychiatr. Clin. 41, 79–93 (2018).
Pagnin, D., de Queiroz, V., Pini, S. & Cassano, G. B. Efficacy of ECT in depression: a meta-analytic review. Focus 6, 155–162 (2008).
doi: 10.1176/foc.6.1.foc155
Ren, J. et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Prog. Neuro Psychopharmacol. Biol. Psychiatry 51, 181–189 (2014).
doi: 10.1016/j.pnpbp.2014.02.004
Menon, V., Varadharajan, N., Faheem, A. & Andrade, C. Ketamine vs electroconvulsive therapy for major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry 80, 639–642 (2023).
pubmed: 37043224
doi: 10.1001/jamapsychiatry.2023.0562
Anand, A. et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N. Engl. J. Med. 388, 2315–2325 (2023).
pubmed: 37224232
doi: 10.1056/NEJMoa2302399
Cole, E. J. et al. Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am. J. Psychiatry 179, 132–141 (2022).
pubmed: 34711062
doi: 10.1176/appi.ajp.2021.20101429
Cirillo, G. et al. Neurobiological after-effects of non-invasive brain stimulation. Brain Stimul. 10, 1–18 (2017).
pubmed: 27931886
doi: 10.1016/j.brs.2016.11.009
Krogh, J., Hjorthøj, C., Speyer, H., Gluud, C. & Nordentoft, M. Exercise for patients with major depression: a systematic review with meta-analysis and trial sequential analysis. BMJ Open 7, e014820 (2017).
pubmed: 28928174
pmcid: 5623558
doi: 10.1136/bmjopen-2016-014820
Schuch, F. B. et al. Exercise for depression in older adults: a meta-analysis of randomized controlled trials adjusting for publication bias. Braz. J. Psychiatry 38, 247–254 (2016).
pubmed: 27611903
pmcid: 7194268
doi: 10.1590/1516-4446-2016-1915
Stubbs, B. et al. Dropout from exercise randomized controlled trials among people with depression: a meta-analysis and meta regression. J. Affect. Disord. 190, 457–466 (2016).
pubmed: 26551405
doi: 10.1016/j.jad.2015.10.019
Firth, J. et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 6, 675–712 (2019). Developed by a Lancet Psychiatry Commission Task Force, this publication provides a detailed overview of how the physical health of people with mental disorders can be addressed.
pubmed: 31324560
doi: 10.1016/S2215-0366(19)30132-4
Cuijpers, P. et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry 19, 92–107 (2020).
pubmed: 31922679
pmcid: 6953550
doi: 10.1002/wps.20701
Cuijpers, P. et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry 13, 56–67 (2014).
pubmed: 24497254
pmcid: 3918025
doi: 10.1002/wps.20089
Breedvelt, J. J. F., Warren, F. C., Segal, Z., Kuyken, W. & Bockting, C. L. Continuation of antidepressants vs sequential psychological interventions to prevent relapse in depression: an individual participant data meta-analysis. JAMA Psychiatry 78, 868–875 (2021).
pubmed: 34009273
doi: 10.1001/jamapsychiatry.2021.0823
Dodd, S. et al. A clinical approach to treatment resistance in depressed patients: what to do when the usual treatments don’t work well enough? World J. Biol. Psychiatry 22, 483–494 (2021).
pubmed: 33289425
doi: 10.1080/15622975.2020.1851052
Rybak, Y. E. et al. Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. Depress. Anxiety 38, 456–467 (2021).
pubmed: 33528865
pmcid: 8049072
doi: 10.1002/da.23135
Bennabi, D. et al. Risk factors for treatment resistance in unipolar depression: a systematic review. J. Affect. Disord. 171, 137–141 (2015).
pubmed: 25305428
doi: 10.1016/j.jad.2014.09.020
Barry, L. C., Abou, J. J., Simen, A. A. & Gill, T. M. Under-treatment of depression in older persons. J. Affect. Disord. 136, 789–796 (2012).
pubmed: 22030136
doi: 10.1016/j.jad.2011.09.038
Nuñez, N. A. et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. J. Affect. Disord. 302, 385–400 (2022).
pubmed: 34986373
pmcid: 9328668
doi: 10.1016/j.jad.2021.12.134
Fava, M. et al. A phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY). J. Clin. Psychiatry 80, 481 (2019).
doi: 10.4088/JCP.19m12928
Papakostas, G. I. et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J. Clin. Psychiatry 81, 6603 (2020).
doi: 10.4088/JCP.19r12889
Turner, E. H. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry 6, 977–979 (2019).
pubmed: 31680014
doi: 10.1016/S2215-0366(19)30394-3
McIntyre, R. S. et al. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J. Affect. Disord. 276, 576–584 (2020).
pubmed: 32871689
doi: 10.1016/j.jad.2020.06.050
Swainson, J. et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: recommandations du groupe de travail du réseau canadien pour les traitements de l’humeur et de l’anxiété (canmat) concernant l’utilisation de la kétamine racémique chez les adultes souffrant de trouble dépressif majeur. Can. J. Psychiatry 66, 113–125 (2021).
pubmed: 33174760
doi: 10.1177/0706743720970860
Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont. Health Technol. Assess. Ser. 16, 1–66 (2016).
pmcid: 4973962
Li, H., Cui, L., Li, J., Liu, Y. & Chen, Y. Comparative efficacy and acceptability of neuromodulation procedures in the treatment of treatment-resistant depression: a network meta-analysis of randomized controlled trials. J. Affect. Disord. 287, 115–124 (2021).
pubmed: 33780827
doi: 10.1016/j.jad.2021.03.019
Bottomley, J. M., LeReun, C., Diamantopoulos, A., Mitchell, S. & Gaynes, B. N. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: a systematic review and meta-analysis. Compr. Psychiatry 98, 152156 (2020).
doi: 10.1016/j.comppsych.2019.152156
Hitti, F. L., Yang, A. I., Cristancho, M. A. & Baltuch, G. H. Deep brain stimulation is effective for treatment-resistant depression: a meta-analysis and meta-regression. J. Clin. Med. https://doi.org/10.3390/jcm9092796 (2020).
doi: 10.3390/jcm9092796
pubmed: 32872572
pmcid: 7564277
[No authors listed.] Physical activity and exercise during pregnancy and the postpartum period: ACOG Committee Opinion, number 804. Obstet. Gynecol. 135, E178–E188 (2020).
doi: 10.1097/AOG.0000000000003772
Lou, Z. Q., Zhou, Y. Y., Zhang, X. & Jiang, H. Y. Exposure to selective noradrenalin reuptake inhibitors during the first trimester of pregnancy and risk of congenital malformations: a meta-analysis of cohort studies. Psychiatry Res. 316, 114756 (2022).
pubmed: 35932572
doi: 10.1016/j.psychres.2022.114756
Meltzer-Brody, S. et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 392, 1058–1070 (2018).
pubmed: 30177236
doi: 10.1016/S0140-6736(18)31551-4
Van Krugten, F., Feskens, K., Busschbach, J., Hakkaart-van Roijen, L. & Brouwer, W. Instruments to assess quality of life in people with mental health problems: a systematic review and dimension analysis of generic, domain-and disease-specific instruments. Health Qual. Life Outcomes 19, 249 (2021).
pubmed: 34727928
pmcid: 8561965
doi: 10.1186/s12955-021-01883-w
Cho, Y. et al. Factors associated with quality of life in patients with depression: a nationwide population-based study. PLoS ONE 14, e0219455 (2019).
pubmed: 31295291
pmcid: 6623963
doi: 10.1371/journal.pone.0219455
Mayers, A. G., Van Hooff, J. C. & Baldwin, D. S. Quantifying subjective assessment of sleep and life‐quality in antidepressant‐treated depressed patients. Hum. Psychopharmacol. Clin. Exp. 18, 21–27 (2003).
doi: 10.1002/hup.438
Pigeon, W. R., Pinquart, M. & Conner, K. Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J. Clin. Psychiatry 73, e1160–e1167 (2012).
pubmed: 23059158
doi: 10.4088/JCP.11r07586
Conradi, H., Ormel, J. & De Jonge, P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychological Med. 41, 1165–1174 (2011).
doi: 10.1017/S0033291710001911
McIntyre, R. S. et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr. Psychiatry 56, 279–282 (2015).
pubmed: 25439523
doi: 10.1016/j.comppsych.2014.08.051
Semkovska, M. et al. Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry 6, 851–861 (2019).
pubmed: 31422920
doi: 10.1016/S2215-0366(19)30291-3
Baune, B. T., Brignone, M. & Larsen, K. G. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int. J. Neuropsychopharmacol. 21, 97–107 (2018).
pubmed: 29053849
doi: 10.1093/ijnp/pyx070
Plana-Ripoll, O. et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet 394, 1827–1835 (2019).
pubmed: 31668728
doi: 10.1016/S0140-6736(19)32316-5
Ormel, J. et al. Disability and treatment of specific mental and physical disorders across the world. Br. J. Psychiatry 192, 368–375 (2008).
pubmed: 18450663
pmcid: 2681238
doi: 10.1192/bjp.bp.107.039107
Machado, M. O. et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med. 16, 112 (2018).
pubmed: 30025524
pmcid: 6053830
doi: 10.1186/s12916-018-1101-z
Saha, S. et al. Co-morbidity between mood and anxiety disorders: a systematic review and meta-analysis. Depress. Anxiety 38, 286–306 (2021).
pubmed: 33225514
doi: 10.1002/da.23113
Saha, S. et al. Comorbidity between mood and substance-related disorders: a systematic review and meta-analysis. Aust. NZ J. Psychiatry 56, 757–770 (2022).
doi: 10.1177/00048674211054740
Pescosolido, B. A. et al. “A disease like any other”? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. Am. J. Psychiatry 167, 1321–1330 (2010).
pubmed: 20843872
pmcid: 4429867
doi: 10.1176/appi.ajp.2010.09121743
Schnyder, N., Panczak, R., Groth, N. & Schultze-Lutter, F. Association between mental health-related stigma and active help-seeking: systematic review and meta-analysis. Br. J. Psychiatry 210, 261–268 (2017).
pubmed: 28153928
doi: 10.1192/bjp.bp.116.189464
Eisenberg, D., Golberstein, E. & Hunt, J. B. Mental health and academic success in college. BE J. Economic Anal. Policy 9, 10.2202/1935-1682.2191 (2009).
Clayborne, Z. M., Varin, M. & Colman, I. Systematic review and meta-analysis: adolescent depression and long-term psychosocial outcomes. J. Am. Acad. Child Adolesc. Psychiatry 58, 72–79 (2019).
pubmed: 30577941
doi: 10.1016/j.jaac.2018.07.896
Finning, K. et al. The association between child and adolescent depression and poor attendance at school: a systematic review and meta-analysis. J. Affect. Disord. 245, 928–938 (2019).
pubmed: 30699878
doi: 10.1016/j.jad.2018.11.055
Alonso, J. et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol. Psychiatry 16, 1234–1246 (2011).
pubmed: 20938433
doi: 10.1038/mp.2010.101
Plana-Ripoll, O. et al. The association between mental disorders and subsequent years of working life: a Danish population-based cohort study. Lancet Psychiatry 10, 30–39 (2023). A population-based cohort study that investigated the association between mental disorders and measures of workforce participation in 5,163,321 individuals.
pubmed: 36480953
doi: 10.1016/S2215-0366(22)00376-5
Greenberg, P. E. et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64, 5373 (2003).
doi: 10.4088/JCP.v64n1211
Chang, S. M., Hong, J.-P. & Cho, M. J. Economic burden of depression in South Korea. Soc. Psychiatry Psychiatr. Epidemiol. 47, 683–689 (2012).
pubmed: 21526429
doi: 10.1007/s00127-011-0382-8
Lovejoy, M. C., Graczyk, P. A., O’Hare, E. & Neuman, G. Maternal depression and parenting behavior: a meta-analytic review. Clin. Psychol. Rev. 20, 561–592 (2000).
pubmed: 10860167
doi: 10.1016/S0272-7358(98)00100-7
Whisman, M. A. & Uebelacker, L. A. Prospective associations between marital discord and depressive symptoms in middle-aged and older adults. Psychol. Aging 24, 184 (2009).
pubmed: 19290750
doi: 10.1037/a0014759
Correll, C. U. et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry 22, 48–74 (2023). This publication provides a review of pharmacotherapy interventions currently being trialled and a detailed review of clinical trial considerations relevant to depression research.
pubmed: 36640403
pmcid: 9840514
doi: 10.1002/wps.21056
Marwaha, S. et al. Novel and emerging treatments for major depression. Lancet 401, 141–153 (2023).
pubmed: 36535295
doi: 10.1016/S0140-6736(22)02080-3
Gordon, J. L. et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry 75, 149–157 (2018).
pubmed: 29322164
pmcid: 5838629
doi: 10.1001/jamapsychiatry.2017.3998
Deligiannidis, K. M. et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry 78, 951–959 (2021).
pubmed: 34190962
doi: 10.1001/jamapsychiatry.2021.1559
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M. J. & Akhondzadeh, S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37, 2093–2100 (2012).
pubmed: 22549115
pmcid: 3398722
doi: 10.1038/npp.2012.58
Sarris, J. et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: the World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J. Biol. Psychiatry 23, 424–455 (2022).
pubmed: 35311615
doi: 10.1080/15622975.2021.2013041
Borrione, L. et al. A study protocol for an ongoing multi-arm, randomized, double-blind, sham-controlled clinical trial with digital features, using portable transcranial electrical stimulation and internet-based behavioral therapy for major depression disorders: the PSYLECT study. Expert Rev. Neurother. 22, 513–523 (2022).
pubmed: 35642516
doi: 10.1080/14737175.2022.2083959
Rosenblat, J. D. & McIntyre, R. S. Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials. J. Affect. Disord. 227, 219–225 (2018).
pubmed: 29102836
doi: 10.1016/j.jad.2017.10.042
El Massry, M., Alaeddine, L. M., Ali, L., Saad, C. & Eid, A. A. Metformin: a growing journey from glycemic control to the treatment of Alzheimer’s disease and depression. Curr. Med. Chem. 28, 2328–2345 (2021).
pubmed: 32900343
doi: 10.2174/0929867327666200908114902
De Giorgi, R. et al. Statins in depression: an evidence-based overview of mechanisms and clinical studies. Front. Psychiatry 12, 702617 (2021).
pubmed: 34385939
pmcid: 8353114
doi: 10.3389/fpsyt.2021.702617
Fava, M. The promise and challenges of drug repurposing in psychiatry. World Psychiatry 17, 28 (2018).
pubmed: 29352538
pmcid: 5775121
doi: 10.1002/wps.20481
Truong, T. T. et al. Integrative analyses of transcriptomes to explore common molecular effects of antipsychotic drugs. Int. J. Mol. Sci. 23, 7508 (2022).
pubmed: 35886854
pmcid: 9325239
doi: 10.3390/ijms23147508
Truong, T. T. et al. Co-expression networks unveiled long non-coding RNAs as molecular targets of drugs used to treat bipolar disorder. Front. Pharmacol. 13, 873271 (2022).
pubmed: 35462908
pmcid: 9024411
doi: 10.3389/fphar.2022.873271
Sarris, J., Pinzon Rubiano, D., Day, K., Galvão-Coelho, N. L. & Perkins, D. Psychedelic medicines for mood disorders: current evidence and clinical considerations. Curr. Opin. Psychiatry 35, 22–29 (2022).
pubmed: 34855694
doi: 10.1097/YCO.0000000000000759
Galvão-Coelho, N. L. et al. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology 238, 341–354 (2021).
pubmed: 33427944
pmcid: 7826317
doi: 10.1007/s00213-020-05719-1
World Health Organization. Comprehensive Mental Health Action Plan 2013–2030 (WHO, 2021).
Naslund, J. A. et al. Digital technology for treating and preventing mental disorders in low-income and middle-income countries: a narrative review of the literature. Lancet Psychiatry 4, 486–500 (2017).
pubmed: 28433615
pmcid: 5523650
doi: 10.1016/S2215-0366(17)30096-2
Espie, C. A., Firth, J. & Torous, J. Evidence‐informed is not enough: digital therapeutics also need to be evidence‐based. World Psychiatry 21, 320 (2022).
pubmed: 35524617
pmcid: 9077620
doi: 10.1002/wps.20993
Torous, J., Nicholas, J., Larsen, M. E., Firth, J. & Christensen, H. Clinical review of user engagement with mental health smartphone apps: evidence, theory and improvements. Evid. Based Ment. Health 21, 116–119 (2018).
pubmed: 29871870
doi: 10.1136/eb-2018-102891
Parker, G. et al. Defining melancholia: a core mood disorder. Bipolar Disord. 19, 235–237 (2017).
pubmed: 28599349
doi: 10.1111/bdi.12501
Milaneschi, Y., Lamers, F., Berk, M. & Penninx, B. W. Depression heterogeneity and its biological underpinnings: toward immunometabolic depression. Biol. Psychiatry 88, 369–380 (2020).
pubmed: 32247527
doi: 10.1016/j.biopsych.2020.01.014
Lynch, C. J., Gunning, F. M. & Liston, C. Causes and consequences of diagnostic heterogeneity in depression: paths to discovering novel biological depression subtypes. Biol. Psychiatry 88, 83–94 (2020).
pubmed: 32171465
doi: 10.1016/j.biopsych.2020.01.012
Glen, S., Simpson, A., Drinnan, D., McGuinness, D. & Sandberg, S. Testing the reliability of a new measure of life events and experiences in childhood: the psychosocial assessment of childhood experiences (PACE). Eur. Child. Adolesc. Psychiatry 2, 98–110 (1993).
pubmed: 29871453
doi: 10.1007/BF02098865
McGorry, P. D. & Hickie, I. B. Clinical Staging in Psychiatry (Cambridge Univ. Press, 2019).
Chekroud, A. M. et al. The promise of machine learning in predicting treatment outcomes in psychiatry. World Psychiatry 20, 154–170 (2021).
pubmed: 34002503
pmcid: 8129866
doi: 10.1002/wps.20882
Tomitaka, S. et al. Distributional patterns of item responses and total scores on the PHQ-9 in the general population: data from the National Health and Nutrition Examination Survey. BMC Psychiatry 18, 108 (2018).
pubmed: 29685128
pmcid: 5913886
doi: 10.1186/s12888-018-1696-9
Forman-Hoffman, V. et al. Screening for major depressive disorder in children and adolescents: a systematic review for the US Preventive Services Task Force. Ann. Intern. Med. 164, 342–349 (2016).
pubmed: 26857836
doi: 10.7326/M15-2259
Walter, H. J. et al. Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. J. Am. Acad. Child Adolesc. Psychiatry 62, 479–502 (2023).
pubmed: 36273673
doi: 10.1016/j.jaac.2022.10.001
Luxton, R. & Kyriakopoulos, M. Depression in children and young people: identification and management NICE guidelines. Arch. Dis. Child. Educ. Pract. 107, 36–38 (2022).
Dwyer, J. B., Stringaris, A., Brent, D. A. & Bloch, M. H. Annual research review: defining and treating pediatric treatment‐resistant depression. J. Child. Psychol. Psychiatry 61, 312–332 (2020).
pubmed: 32020643
pmcid: 8314167
doi: 10.1111/jcpp.13202